SLIDE 1
COMPANY PRESENTATION 2015 Company Profile Discovery & - - PowerPoint PPT Presentation
COMPANY PRESENTATION 2015 Company Profile Discovery & - - PowerPoint PPT Presentation
COMPANY PRESENTATION 2015 Company Profile Discovery & preclinical stage ADME-Tox CRO Founded in March 2011 Located in Oulu, Finland Serving customers from small Biotechs to Big Pharma Customers in 21 countries on 4 continents We Make a
SLIDE 2
SLIDE 3
Specialised in drug metabolism, drug interactions, bioanalysis and pharmacokinetics 100 peer reviewed scientific papers - expertise in ADME & medical biochemistry Tailored and optimised studies - scientific & technical quality with consistency Strong expertise in analytical technologies (LC/MS and NMR) Continuous service development and adaption of customers’ processes
We Make a Difference
SLIDE 4
Service Portfolio 1/2
- Microsomes, S9, rec-enzymes, hepatocytes
- Metabolic stability / clearance
- Metabolite identification
- Extrahepatic metabolism
- CYP/UGT/SULT phenotyping
- Reactive metabolite screening
- PBPK modeling
- CYP and UGT Inhibition, TDI/MDI/MBI
- CYP and UGT Induction
- Non-CYP inhibition
- In-life part conducted with a partner
- Mouse, rat, rabbit, guinea pig, pig, dog,
monkey
- UPLC/MS/MS or UPLC/HR-MS
- Plasma, urine, feces, brain homogenates,
- ther tissue homogenates
- Method development and validation
SLIDE 5
Service Portfolio 2/2
- Permeability (Caco2/MDCK)
- P-gp or BCRP (efflux & inhibition)
- Uptake transporter assays
- Cytotoxicity
- Genotoxicity (AMES, MNT)
- Cardiotoxicity
- Mechanistic tox assays (oxidative stress,
mitochondiral toxicity, caspase 3/7 activity)
- Solubility (buffer & intestinal/gastric fluids)
- Lipophilicity (logD)
- Plasma protein & brain homogenate binding & in
vitro binding (RED)
- Plasma stability, chemical stability
- Identification of degradation products or impurities
- Metabolic stability
- CYP-inhibition screening
- CYP-induction
- Permeability (Caco2)
SLIDE 6